A Phase I Study of GSK3145095 Immunotherapy in Patients with Advanced Pancreatic Cancer

Full Title

A Phase I/II, Open-Label Study to Investigate the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of GSK3145095 Administered Alone and in Combination with Anticancer Agents Including Pembrolizumab in Adult Participants with Selected Advanced Solid Tumors

Purpose

The purpose of this study is to determine the highest dose of the investigational immunotherapy drug GSK3145095 that can be given safely in patients with metastatic pancreatic cancer. GSK3145095 works by blocking a protein that prevents the immune system from fighting cancer. Blocking this protein may strengthen the immune system’s ability to attack cancer cells. It is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have metastatic pancreatic cancer that continues to grow despite one or two regimens of treatment for advanced disease.
  • At least 2 weeks must pass since the completion of prior therapy and entry into the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Anna Varghese at 646-888-4308.

Protocol

19-095

Phase

I/II

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators